Titre Image Guided Intensity Modulated External Beam Radiochemotherapy and MRI Based Adaptive BRAchytherapy in Locally Advanced CErvical Cancer
Protocole ID EMBRACE 2
ClinicalTrials.gov ID NCT03617133
Type(s) de cancer Col
Phase Phase II
Stade Localement avancé
Type étude Traitement
      5415 boul. de l'Assomption, Montréal, QC, H1T2M4
Ville Montréal
Investigateur(trice) principal(e) Dr Israël Fortin
Coordonnateur(trice) Véronique Tran
 514-252-3400 poste 3227
Statut Actif en recrutement
Critètes d'éligibilité
  • Cancer of the uterine cervix considered suitable for curative treatment with definitive radio-(chemo)therapy including MRI guided BT
  • Positive biopsy showing squamous-cell carcinoma, adenocarcinoma or adeno-squamous cell carcinoma of the uterine cervix.
  • Staging according to FIGO and TNM guidelines
  • MRI of pelvis at diagnosis is performed
  • MRI, CT or PET-CT of the retroperitoneal space and abdomen at diagnosis is performed
  • MRI with the applicator in place at the time of (first) BT will be performed
  • Para-aortic metastatic nodes below L1-L2 are allowed
  • Patient informed consent
Critètes d'exclusion
  • Other primary malignancies except carcinoma in situ of the cervix and basal cell carcinoma of the skin
  • Small cell neuroendocrine cancer, melanoma and other rare cancers in the cervix
  • Metastatic disease above and beyond the retroperitoneal para-aortic L1-L2 interspace
  • Previous pelvic or abdominal radiotherapy
  • Previous total or partial hysterectomy
  • Combination of preoperative radiotherapy with surgery
  • Patients receiving BT only
  • Patients receiving EBRT only
  • Patients receiving neo-adjuvant chemotherapy or other forms of antineoplastic treatment apart from weekly concomitant cisplatin (40 mg/2). However, adjuvant chemotherapy in the form of 4 courses of 3 weekly Carboplatin (AUC 5) and Paclitaxel (155 mg/m2) is allowed according to departmental policy.
  • Contra indications to MRI
  • Contra indications to BT